trending Market Intelligence /marketintelligence/en/news-insights/trending/jXoDKIawKTjwS0-sFaqihA2 content esgSubNav
In This List

Concert's hair loss treatment reduces baldness in mid-stage study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Concert's hair loss treatment reduces baldness in mid-stage study

Concert Pharmaceuticals Inc.'s experimental treatment CTP-543 reduced spot baldness in alopecia areata patients, a disease in which the person's immune system attacks hair follicles, causing hair loss.

According to the results of a phase 2 trial, the stronger of the three doses of CTP-543 — 8 milligrams and 12 milligrams — reduced hair fall by at least 50% in 58% and 47% of patients studied, respectively, while the weakest dose — 4 milligrams — did not yield any statistically significant benefit. In 2017, the U.S. Food and Drug Administration had briefly put this phase 2 trial on hold.

CTP-543 was being studied against placebo in 149 patients for 24 weeks and has received the U.S. FDA's fast-track designation. It is also at the center of a patent lawsuit filed by Incyte Corp. in 2018.

The company now plans to advance the medicine in phase 3 testing next year.